Oil Prices Rebound in Asia as Venezuela Sanctions Risks Offset Ukraine Peace Hopes 
Fed Rate Cut Signals Balance Between Inflation and Jobs, Says Mary Daly 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Pfizer Secures $10 Billion Deal for Obesity Drug Developer Metsera, Outbids Novo Nordisk 
U.S. Experts to Reassess Newborn Hepatitis B Vaccination Guidelines Amid Growing Debate 
Global Markets Slide as Tech Stocks Sink, Yields Rise, and AI Concerns Deepen 
Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
Westpac Director Peter Nash Avoids Major Investor Backlash Amid ASX Scrutiny 
Japan Business Sentiment Hits Four-Year High, Boosting Expectations of BOJ Rate Hike 
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
China’s November Economic Data Signals Slowing Industrial Output and Weak Consumer Demand 
Innovent’s Xinermei Intensifies Weight-Loss Drug Battle in China 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
S&P 500 Slides as AI Chip Stocks Tumble, Cooling Tech Rally 
An Abbott Laboratories processing plant in Sturgis, Mich being investigated for cases of infant illness is being allowed to release some product that was processed before it was shut down.
Certain goods designed for infants and people with specific medical issues will be given out for free.
Abbott officials claimed they're doing it at the FDA's request to help with shortages of these specialty feeding items.
After a recall of Similac infant formula and other products in February, the Sturgis plant was forced to shut down. Cronobacter bacteria had infected many infants, one of whom died; cronobacter was identified in their systems and the formula they had drunk. Cronobacter bacteria were discovered in the factory during an inspection.
However, further examination revealed that the cronobacter strain that caused the infections was not the same as the one detected in the plant and that no food-contact surfaces had been contaminated.
On a case-by-case basis, Abbott is issuing cases of a nutrition supplement for people with uncommon metabolic diseases and others. The corporation stated that it is doing so at the FDA's request to assist reduce shortages.
